What we do Gland Pharma manufactures and sells generic injectable pharmaceutical formulations globally, specializing in sterile injectables, oncology, and ophthalmics. |
Founded in 1,978 |
Market share Leading player in global generic injectables with strong presence in US, Europe, Canada, Australia, and India. |
Problem solved Provides high-quality, affordable injectable medicines, addressing supply chain and cost issues in pharmaceutical injectables. |
Top clients or who we serve B2B focus serving global pharmaceutical companies, including US and European markets, with contract manufacturing and complex injectables. |
Key management Executive Chairman Srinivas Sadu, CEO Shyamakant Giri; strong leadership with industry and global pharma experience. |
Our journey and innovations Founded in 1978, expanded globally with multiple FDA-approved plants, acquired Cenexi, launched complex products and COVID vaccine contracts. |
Where we operate Operations in India, USA, Europe, Canada, Australia, Singapore; exports to over 60 countries worldwide. |
Top products or what we offer High-quality sterile injectables, oncology drugs, ophthalmic products, Ready-to-Use infusion bags, and complex drug-device combinations. |
Top brands Flagship sterile injectable portfolio; key products include Eribulin, Dexrazoxane, Sputnik V vaccine; evolving complex oncology and GLP-1 injectables. |
Raw materials needed Active Pharmaceutical Ingredients for sterile injectables, oncology drugs, and complex formulations. |
Raw materials supplier Produced in-house API facilities to control quality and supply chain risks; supplemented by global suppliers as needed. |
Recurring vs cyclical contribution Majority of revenue from recurring contract manufacturing and long-term partnerships in injectable generics. |
Our industry position Top global player in generic sterile injectables with expanding capabilities in complex and specialty injectables. |
Financial highlights FY25 consolidated revenue ₹58,301 million, net profit ₹6,985 million, EBITDA margin ~25%, strong cash flows, and steady growth. |
Geographical revenue split Revenue mix: USA ~47%, Europe ~18%, India ~8%, Canada, Australia, Rest of World ~27%. |
Order book Large ANDA pipeline with 384 US filings; steady contract manufacturing orders for oncology and complex injectables. |
Whats driving growth Growth fueled by new product launches, complex injectables pipeline, capacity expansion, and strategic acquisitions. |
Our future plans Expand complex product portfolio, increase manufacturing capacity globally, invest in R&D, and grow drug-device combinations. |
Our green promise Committed to sustainability and compliance with environmental regulations at manufacturing sites. |
Our people and values Employs over 2,000 professionals with emphasis on innovation, quality, diversity, and employee welfare. |
Key challenges ahead Regulatory risks, competitive pricing pressures, supply chain management, and integration of acquired entities. |
Interesting facts First Indian company to commercially supply complex injectables globally; zero FDA warning letters historically. |
Risks and strategy Mitigates regulatory risks via robust compliance; pursues innovation and global expansion to maintain market leadership. |
